Aurora Mobile Congratulates Zhipu on Successful Hong Kong Listing

(NASDAQ:JG), SHENZHEN, China, Jan. 08, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today extended its congratulations to Knowledge Atlas Technology Joint Stock Company Limited, also known as Zhipu, on its successful listing on the Main Board […]

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma expand collaboration from early development to lateâ€'stage and commercial manufacturing of VMX-C001 VMXâ€'C001 builds on strong regulatory momentum, including FDA Fast Track Designation and PMDA Phase 1 waiver, as it progresses toward a global Phase 3 trial Manufacturing will be transferred from Rentschler Biopharma site in Laupheim (Germany) to Milford, MA

Xali Gold Commences Work on Pico Machay Gold Project in Peru

(TSX-V:XGC), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that work has commenced on the recently acquired Pico Machay Gold Project (“Pico Machay” or the “Project”). Xali Gold has commenced field work with the initiation of community engagement in anticipation of

Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target

(TSX-V:BRW),(OTC US:BRWXF),(Other OTC:BRWXF),(Boerse Frankfurt – Freiverkehr:1XQ), MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company“) is very pleased to announce a maiden, open-pit Mineral Inferred Resource Estimate (“MRE“) of 52.2 million tonnes (“Mt“) grading 1.08% Li2O and 131ppm Ta2O5 for its wholly owned Mirage Project located

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill(R) for the Treatment of Obesity in Collaboration with ProGen

(NasdaqGM:RANI), – A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill(R) capsule versus subcutaneous injection – SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the

Surge Copper Advances Berg Toward Pre-Feasibility with Successful 2025 Drilling and Data Validation Program

(TSX-V:SURG),(OTC US:SRGXF),(Other OTC:SRGXF),(Boerse Frankfurt – Freiverkehr:G6D2), Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to report results from its 2025 multidisciplinary drilling and field program at the 100%-owned Berg Project in central British Columbia. The program was designed to

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

(NASDAQ:IRD), – Multi-asset pipeline with significant targeted data readouts and milestones – – Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 – – Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment – – Corporate presentation at J.P. Morgan Healthcare Conference on Thursday, January 15, at 8:15

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

(NASDAQ:AMRN), DUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025 operational accomplishments, and outlined 2026 priorities in advance of business development and investor meetings in San Francisco

Woof Gang Achieves Record Growth in 2025

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) — Woof Gang Bakery & Grooming (“Woof Gang” or “the Company”), the neighborhood pet grooming and treat boutique, today announced record-breaking results for 2025, reaching $150m in system wide sales, a 25% YoY increase. The sales reflect a year of significant growth across strategic regions in the Midwest, Northeast,

Scroll to Top